Prevalence of Sarcopenia and Its Geriatric Features

NCT ID: NCT02664376

Last Updated: 2018-01-26

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

834 participants

Study Classification

OBSERVATIONAL

Study Start Date

2016-01-01

Study Completion Date

2018-01-18

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The goal of this study is to determine the prevalence of sarcopenia in a geriatric hospital ward.

Sarcopenia is defined by a loss of muscle mass, loss of muscle strength and loss of muscle quality. It is a geriatric syndrome that, to this date, is not systematically tracked in clinical practice.

In order to detect sarcopenia, the investigators will use the operational definition proposed by the European Working Group (EWGSOP) involving the measure of three parameters, namely the speed of walking, the muscle strength and the measurement of the muscular mass.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Sarcopenia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Geriatric ward population

Every patient aged over 65 admitted in the unit 83 of the Geriatry Department, CHU Brugmann Hospital, undergoes a global geriatric evaluation at the end of its hospitalisation stay, including sarcopenia detection.

Sarcopenia detection

Intervention Type OTHER

The assessment of sarcopenia is performed according to the recommendations of the EWGSOP (European Working Group on Sarcopenia in Older people). Three measurements are made:

* Muscle mass measurement by dual energy X-ray absorptiometry (DEXA).
* Walking speed measurement
* Hand grip test

A diagnosis of sarcopenia is established if the walking speed is inferior to 0.8 m/sec, the muscular strength is low and the muscular mass is low.

Data regarding the geriatric characteristics of this sarcopenic population will be collected.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Sarcopenia detection

The assessment of sarcopenia is performed according to the recommendations of the EWGSOP (European Working Group on Sarcopenia in Older people). Three measurements are made:

* Muscle mass measurement by dual energy X-ray absorptiometry (DEXA).
* Walking speed measurement
* Hand grip test

A diagnosis of sarcopenia is established if the walking speed is inferior to 0.8 m/sec, the muscular strength is low and the muscular mass is low.

Data regarding the geriatric characteristics of this sarcopenic population will be collected.

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* To be admitted in the unit 83 of the Geriatric Departement of the CHU Brugmann hospital, from 10/01/2016 till 30/03/2017.

Exclusion Criteria

* Patients unable to consent or without representatives
* Patients unable to perform the hand- grip test, the walk test or measurement of the body components by DEXA
* Patients in severe pain
* Bedridden patients
* Patients for which a clear therapeutic abstention has been established
* Language barriere that cannot be overcome
* Patients unable to walk without the help of a third person
Minimum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Brugmann University Hospital

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Murielle Surquin

Head of clinic

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Robin Barré, MD

Role: PRINCIPAL_INVESTIGATOR

CHU Brugmann

Murielle Surquin, MD

Role: PRINCIPAL_INVESTIGATOR

CHU Brugmann

Florence Benoît, MD

Role: PRINCIPAL_INVESTIGATOR

CHU Brugmann

Marie Claessens, MD

Role: PRINCIPAL_INVESTIGATOR

CHU Brugmann

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

CHU Brugmann

Brussels, , Belgium

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Belgium

References

Explore related publications, articles, or registry entries linked to this study.

Cruz-Jentoft AJ, Baeyens JP, Bauer JM, Boirie Y, Cederholm T, Landi F, Martin FC, Michel JP, Rolland Y, Schneider SM, Topinkova E, Vandewoude M, Zamboni M; European Working Group on Sarcopenia in Older People. Sarcopenia: European consensus on definition and diagnosis: Report of the European Working Group on Sarcopenia in Older People. Age Ageing. 2010 Jul;39(4):412-23. doi: 10.1093/ageing/afq034. Epub 2010 Apr 13.

Reference Type BACKGROUND
PMID: 20392703 (View on PubMed)

Baumgartner RN, Koehler KM, Gallagher D, Romero L, Heymsfield SB, Ross RR, Garry PJ, Lindeman RD. Epidemiology of sarcopenia among the elderly in New Mexico. Am J Epidemiol. 1998 Apr 15;147(8):755-63. doi: 10.1093/oxfordjournals.aje.a009520.

Reference Type BACKGROUND
PMID: 9554417 (View on PubMed)

Cesari M, Kritchevsky SB, Newman AB, Simonsick EM, Harris TB, Penninx BW, Brach JS, Tylavsky FA, Satterfield S, Bauer DC, Rubin SM, Visser M, Pahor M; Health, Aging and Body Composition Study. Added value of physical performance measures in predicting adverse health-related events: results from the Health, Aging And Body Composition Study. J Am Geriatr Soc. 2009 Feb;57(2):251-9. doi: 10.1111/j.1532-5415.2008.02126.x.

Reference Type BACKGROUND
PMID: 19207142 (View on PubMed)

Lauretani F, Russo CR, Bandinelli S, Bartali B, Cavazzini C, Di Iorio A, Corsi AM, Rantanen T, Guralnik JM, Ferrucci L. Age-associated changes in skeletal muscles and their effect on mobility: an operational diagnosis of sarcopenia. J Appl Physiol (1985). 2003 Nov;95(5):1851-60. doi: 10.1152/japplphysiol.00246.2003.

Reference Type BACKGROUND
PMID: 14555665 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

CHUB-sarcopenia

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.